A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Associated With Menopause and Hot Flashes, sponsored by Bayer. Completed at 86 sites in 9 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.
Among the 13 studies testing elinzanetant in Hot Flashes, this one has the largest enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 4th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4
First in 2016; this study’s year is marked. 5 started in 2021.
This study's enrollment of 628 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 64 across the 13 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 1 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 3rd largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 3, and was the 9th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing elinzanetant in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.
The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people.
In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo is a treatment that looks like a medicine but does not have any medicine in it. To compare these study treatments, the participants will record information about their hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe they are. They will study the results from before treatment and after 12 weeks of treatment.
The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants will take the study treatments for 52 weeks.
During the study, the participants will visit their study site approximately 11 times and perform 2 visits by phone. Each participant will be in the study for approximately 62 weeks.
During the study, the participants will:
The doctors will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
, defined as:
Exclusion Criteria:
Untreated hyperthyroidism or hypothyroidism.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 120 mg elinzanetant orally once daily.
Drug: Elinzanetant (BAY3427080)
Participants will receive matching placebo orally once daily.
Drug: Placebo
120 mg elinzanetant orally once daily
Matching placebo orally once daily.
Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])
The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a "sensation of heat without sweating", moderate HF are defined as a "sensation of heat with sweating, but able to continue activity", and severe HF are defined as a "sensation of heat with sweating, causing cessation (stopping) of activity".
Time frame: Baseline to Week 12
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time.
The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.
Time frame: Baseline to Week 56
Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time
The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.
Time frame: Baseline to Week 56
The study was conducted at 75 study centers in North America and in several countries in Europe, between 27-Aug-2021 (first participant first visit) and 12-Feb-2024 (last participant last visit).
| Milestone | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| Started | 313 | 315 |
| Received treatment | 312 | 315 |
| Completed | 222 | 231 |
| Not completed | 91 | 84 |
| Withdrew: Adverse event | 17 | 2 |
| Withdrew: Lack of efficacy | 0 | 6 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Non-compliance with study drug | 2 | 3 |
| Withdrew: Other reason | 4 | 3 |
| Withdrew: Physician decision | 1 | 4 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Randomized by mistake | 0 | 2 |
| Withdrew: Withdrawal by subject | 21 | 28 |
| Withdrew: Technical problems | 0 | 1 |
| Withdrew: Completed post-treatment/fu visits | 41 | 31 |
The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a "sensation of heat without sweating", moderate HF are defined as a "sensation of heat with sweating, but able to continue activity", and severe HF are defined as a "sensation of heat with sweating, causing cessation (stopping) of activity".
| Number of HF | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| Baseline | 6.71 ± 7.15 | 6.81 ± 6.15 |
| Change from Baseline | -5.40 ± 7.29 | -3.50 ± 4.96 |
The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.
| T-score | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| Baseline | 57.35 ± 6.66 | 57.96 ± 7.63 |
| Change from baseline to Week 1 | -5.19 ± 7.17 | -1.60 ± 5.39 |
| Change from baseline to Week 2 | -6.78 ± 7.96 | -2.89 ± 6.78 |
| Change from baseline to Week 3 | -7.67 ± 8.24 | -3.34 ± 6.88 |
| Change from baseline to Week 4 | -7.70 ± 8.27 | -3.81 ± 6.98 |
| Change from baseline to Week 8 | -7.98 ± 8.58 | -4.36 ± 7.64 |
| Change from baseline to Week 12 | -7.97 ± 8.04 | -5.26 ± 8.02 |
| Change from baseline to Week 18 | -8.83 ± 9.05 | -5.77 ± 7.82 |
| Change from baseline to Week 24 | -9.77 ± 9.00 | -5.85 ± 7.79 |
| Change from baseline to Week 36 | -9.20 ± 8.74 | -5.88 ± 8.38 |
| Change from baseline to Week 52 | -9.36 ± 8.41 | -5.73 ± 7.91 |
| Change from baseline to Week 56 (Follow-up) | -5.83 ± 8.71 | -5.38 ± 7.50 |
The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.
| Scores on a scale | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| Baseline | 4.10 ± 1.21 | 4.41 ± 1.37 |
| Change from baseline to Week 4 | -0.94 ± 1.22 | -0.67 ± 1.21 |
| Change from baseline to Week 8 | -1.07 ± 1.24 | -0.86 ± 1.18 |
| Change from baseline to Week 12 | -1.10 ± 1.25 | -0.95 ± 1.32 |
| Change from baseline to Week 18 | -1.30 ± 1.32 | -1.11 ± 1.40 |
| Change from baseline to Week 24 | -1.25 ± 1.17 | -1.15 ± 1.37 |
| Change from baseline to Week 36 | -1.18 ± 1.21 | -1.02 ± 1.42 |
| Change from baseline to Week 52 | -1.30 ± 1.33 | -1.11 ± 1.35 |
| Change from baseline to Week 56 (Follow-up) | -0.82 ± 1.25 | -1.04 ± 1.59 |
Collected over Adverse events tables: up to 14 days from the last drug intake, up to 54 weeks. All-cause mortality table: after signing informed consent up to the last contact per participant, up to 62 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elinzanetant (BAY3427080) | 0/313 (0%) | 13/313 (4.2%) | 85/313 (27.2%) |
| Placebo | 0/314 (0%) | 6/314 (1.9%) | 73/314 (23.2%) |
| Event | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/313 | 0/314 |
| VertigoEar and labyrinth disorders | 1/313 | 0/314 |
| EpiglottitisInfections and infestations | 1/313 | 0/314 |
| Fusobacterium infectionInfections and infestations | 1/313 | 0/314 |
| Meningitis meningococcalInfections and infestations | 1/313 | 0/314 |
| ConcussionInjury, poisoning and procedural complications | 1/313 | 0/314 |
| InjuryInjury, poisoning and procedural complications | 1/313 | 0/314 |
| Blood glucose increasedInvestigations | 1/313 | 0/314 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/313 | 1/314 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 1/313 | 0/314 |
| Event | Elinzanetant (BAY3427080) | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 22/313 | 32/314 |
| HeadacheNervous system disorders | 30/313 | 22/314 |
| FatigueGeneral disorders | 21/313 | 9/314 |
| NasopharyngitisInfections and infestations | 15/313 | 21/314 |
| SomnolenceNervous system disorders | 16/313 | 4/314 |
| Age, Continuous(Years) | Elinzanetant (BAY3427080) | Placebo | Total |
|---|---|---|---|
| Mean | 54.6 ± 4.7 | 54.9 ± 5.0 | 54.7 ± 4.8 |
| Sex: Female, Male(Participants) | Elinzanetant (BAY3427080) | Placebo | Total |
|---|---|---|---|
| Female | 313 | 315 | 628 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Elinzanetant (BAY3427080) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 34 | 34 | 68 |
| Not Hispanic or Latino | 266 | 273 | 539 |
| Unknown or Not Reported | 13 | 8 | 21 |
| Race (NIH/OMB)(Participants) | Elinzanetant (BAY3427080) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 51 | 44 | 95 |
| White | 240 | 253 | 493 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 19 | 15 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Aug 2021 to primary completion in Mar 2023, 19 months.
Results were first posted in Dec 2025, 2 years 8 months after primary completion. A results delay was requested in Mar 2024.
Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant